Beshear helps break ground on $20M facility in Muhlenberg County
The new operation is located at Paradise Regional Industrial Park in Muhlenberg County. Officials say the new site includes updated equipment and increased operational space to meet growing consumer demand and allow growth in sales.
'Kentucky's manufacturing industry remains a key catalyst for our continued economic momentum and thriving economy,' Governor Beshear said. 'Today's groundbreaking event is an exciting step for not only BE&E, but for the community and families of Muhlenberg County. These 250 job opportunities will provide a substantial economic boost to the region, and I appreciate BE&E for their belief in the commonwealth and our people.'
Biomass Engineering and Equipment supplies machinery and support services to various industries, including animal feed, chemical production, biofuels and advanced recycling.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
E&P, Midstream Executives Plan PDP-Weighted SPAC, Dynamix III
Former E&P and midstream executives are planning a SPAC, Dynamix Corp. III, to build a PDP-focused E&P as private equity funds begin to exit some of their $75 billion in portfolio holdings. The Houston-based special purpose acquisition corporation (SPAC) expects to sell 15 million units in a $150 million raise. Shares are to trade on the Nasdaq as DNMXU, according to an S-1 filing with the Securities and Exchange Commission. Dynamix III's CEO, Andrea 'Andrejka' Bernatova, is a director at Salt Creek Midstream and Regenerate Technology Global. Prior, she was the CFO of Enchanted Rock Energy, Goodnight Midstream and Core Midstream and was a founding team member of PennTex Midstream Partners, which was sold to Energy Transfer Partners and EagleClaw Midstream in 2016. Bernatova's first Dynamix SPAC, Esgen, merged with Sunergy Renewables and renamed Zero Energy. Her second Dynamix currently plans to merge with The Ether Machine. Nader Daylami, the new SPAC's CFO, was formerly the executive vice president of finance and business development for Bruin, a North Dakota-focused E&P sold in 2021 to Enerplus Corp., which is now owned by Chord Energy. Prior, he held roles at Ursa Resources Group II, an oil and gas producer in the Eagle Ford and in western Colorado. Daylami was CFO at Dynamix I and is CFO of Dynamix II. Philip Rajan, Dynamix III's executive vice president, M&A and strategy, was a senior vice president at energy merchant bank Intrepid. He is currently vice president of M&A for Dynamix II. The sole book-running manager for the Dynamix III SPAC is Cohen & Company Capital Markets. Cohen is also the sole book-running manager of former NGP partner Chris Sorrells' recently filed plan to IPO a third SPAC, Spring Valley Acquisition III, to invest in the oil and gas, decarbonization or metals mining sectors. $75 billion Bernatova stated in the new SPAC's S-1, 'We believe there is a unique and timely opportunity to achieve attractive returns by acquiring established E&P, midstream and oilfield service assets within overlooked basins.' The plan is to buy PDP-weighted property. 'Despite current market sentiment, projections for crude oil and natural gas suggest demand growth for many years before reaching its peak, while E&P companies have reacted to low commodity prices as a result of oversupply by reducing growth capital spending,' she reported. Meanwhile, she expects property to come onto the market as 'aging private equity funds in the energy sector will drive substantial sales in the coming years as a result of capital invested by private equity firms from 2009 to 2018.' The backlog in the E&P, midstream and oilfield services spaces is approximately $75 billion, she estimates. Meanwhile, 'these aging private equity funds may require liquidity within the next five years,' she wrote. Overall, 'the global energy system remains in the early stages of a multi-decade transformation toward a lower-carbon, more sustainable future,' she added. In that area, 'we intend to focus on acquisition opportunities that offer attractive, scalable growth profiles and are positioned to contribute meaningfully to the energy transition.' Also, she added, there is investment opportunity in the power space. 'Durable power delivery will be central to enabling future economic growth, and we aim to invest in the companies that make it possible.' Ex-energy bankers Bernatova began her career as an investment banker at Morgan Stanley and Credit Suisse and held investment roles at The Blackstone Group and at Abu Dhabi's $250 billion fund Mubadala Development Co. Daylami was also an investment banker at Morgan Stanley where he worked in energy M&A and finance. Rajan worked in energy M&A and finance at Credit Suisse and held energy-desk roles at KeyBanc Capital Markets and Duff & Phelps. Other recently filed SPACs involving the energy space include Pyrophyte Acquisition II, which raised $175 million in July and is led by retired Weatherford International CEO Bernard Duroc-Danner. Energy finance executive Jerry Silvey raised $420 million in July for his EQV Ventures Acquisition II. His first EQV plans to buy Anadarko Basin-focused Presidio Petroleum, which produces 26,000 boe/d, for $480 million, including debt. Meanwhile, Riverstone Holdings co-founder David Leuschen plans to raise $250 million in a SPAC, CH4 Natural Solutions Acquisition. He reported in the S-1 that CH4 intends to buy and build a company that would 'benefit from accelerated methane-mitigation initiatives at scale.' Sign in to access your portfolio
Business Insider
3 hours ago
- Business Insider
Why Is ProPhase Labs Stock (PRPH) Up 25% Today?
ProPhase Labs (PRPH) stock took off on Tuesday after the consumer healthcare company announced a patent update. The U.S. Patent and Trademark Office has issued its approval for a patent that covers its biomarker-based systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma. This is a type of cancer that develops in the glandular cells lining the esophagus. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ted Karkus, CEO of ProPhase Labs, said, 'With this newly issued patent, we believe we are well positioned to accelerate commercialization and broaden clinical access to BE-Smart.' BE-Smart is the company's molecular diagnostic, which has achieved a greater than 95% technical success rate in detecting its patented panel of biomarkers. Investors will also note that ProPhase Labs will release its Q2 2025 earnings report tomorrow. Wall Street's estimates are for earnings per share of -15 cents and revenue of $3.55 million. ProPhase Labs has historically missed estimates more times than it has surpassed them. ProPhase Labs Stock Movement Today ProPhase Labs stock was up 26.98% in pre-market trading on Tuesday, following a 9.77% drop yesterday. Traders will also note that the shares have fallen 62.93% year-to-date and 88.6% over the past 12 months. Today's movement came with heavy trading, as some 61 million shares changed hands, compared to a three-month daily average of about 903,000 units. Is ProPhase Labs Stock a Buy, Sell, or Hold? Turning to Wall Street, analysts' coverage of ProPhase Labs is lacking. Fortunately, TipRanks' AI analyst Spark has it covered. Spark rates PRPH stock a Neutral (46) with a 50-cent price target, representing a potential 77.49% upside for the shares.
Business Upturn
8 hours ago
- Business Upturn
Global High-Throughput Screening Market to Surpass USD 50.2 Billion by 2029
By GlobeNewswire Published on August 13, 2025, 05:30 IST Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) — North America Leads Today, Asia Pacific to Record Fastest Growth The global high throughput screening market, valued at US$25.7 billion in 2023, stood at US$28.8 billion in 2024 and is projected to advance at a resilient CAGR of 11.8% from 2024 to 2029, culminating in a forecasted valuation of US$50.2 billion by the end of the period. This growth is propelled by surging R&D investments in drug discovery, strategic government funding, and the increasing adoption of automation in life sciences research. Download PDF Brochure: What Is Driving the Market Now? HTS adoption is accelerating due to innovations in automation, miniaturization, and high-content screening, which significantly reduce discovery timelines and enhance precision in identifying therapeutic candidates. Grants such as the USD 7.8 million awarded to the University of Pittsburgh for advanced drug discovery systems underscore growing institutional and government commitment to high-impact research. Why Does This Matter for Global Pharma and Biotech Leaders? The market represents a critical enabler for competitive advantage in lead discovery, target validation, compound profiling, and hit identification—processes essential for pipeline acceleration. While high instrument costs remain a barrier, particularly for automated liquid handling and high-resolution imaging systems, emerging markets such as China and India offer lucrative opportunities with strong government support and an expanding pharmaceutical manufacturing base. Who Are the Key Stakeholders? The HTS ecosystem spans pharmaceutical giants, biotechnology innovators, academic institutions, and technology providers, all collaborating to enhance assay development and manage the rising complexity of biological data. The consumables segment—driven by recurring purchases of reagents and kits—dominates the market, ensuring steady demand as HTS workflows expand globally. Request Sample Pages: Where Is Growth Coming From? North America currently leads, fueled by advanced HTS infrastructure, robust funding for life science research, and a thriving biotech sector. Asia Pacific is projected to be the fastest-growing region, supported by a diverse patient base, strong pharmaceutical capabilities, and favorable regulatory environments. How Are Market Leaders Responding? Thermo Fisher Scientific Inc. maintains global leadership through an extensive portfolio of automated systems, screening instruments, and consumables, underpinned by 3% annual R&D investment and strategic alliances. Agilent Technologies, Inc. offers highly customizable workflows via BioTek detection instruments and Gen6 software, strengthened by acquisitions such as e-MSion (US) to enhance mass spectrometry capabilities. Merck KGaA delivers a diverse portfolio of reagents, instruments, software, and services, leveraging global reach and deep customer relationships across pharma, academia, and government sectors. Market Outlook As automation, AI-driven data analysis, and advanced assay development converge, HTS will remain at the forefront of pharmaceutical innovation. Decision-makers who strategically invest in HTS capabilities today will be best positioned to accelerate therapeutic pipelines, capture market share, and deliver faster, more targeted treatments to market. For more information, Inquire Now Discover Connected Healthcare Market Opportunities: Drug Screening Market Carrier Screening Market Cell based Assays Market Label Free Detection Market Life Science Instrumentation Market Get access to the latest updates on High-Throughput Screening Companies and High-Throughput Screening Market Size Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
